FDA Drops A BOMBSHELL – COVID Vaccine UPDATE!

In a bombshell development, the Food and Drug Administration has expanded health risk advisories for Pfizer and Moderna COVID-19 vaccines, citing myocarditis concerns.

See the tweet below!

These updates are crucial for protecting young males, the group most affected by this side effect.

As myocarditis cases rise, the FDA’s actions echo the public’s growing distrust towards current guidelines.

The FDA requested updated labels from Pfizer/BioNTech and Moderna highlighting cardiovascular risks.

The warnings focus on myocarditis and pericarditis, specifically affecting young males aged 16 to 25.

Previously, warnings for Pfizer covered boys 12 to 17, and for Moderna, males 18 to 24.

These changes stem from abnormal cardiac MRI findings showing myocardial injury, indicating new safety concerns.

The FDA considers these changes imperative, providing Pfizer and Moderna with 30 days to propose or contend label updates.

As myocarditis is already noted as a side effect, the updated warnings aim to enhance transparency.

The Department of Health and Human Services supports this move, encouraging clear communication about vaccine risks and benefits.

Under the new Trump administration, emphasis on high-risk groups aligns with FDA policy shifts.

Expanded vaccine labels and limited access reflect a broader risk-based framework.

Trump officials plan to limit vaccines to individuals 65+ and those with high-risk conditions, addressing critical care needs while acknowledging societal apprehensions toward mass vaccination.

Research supports the safety of mRNA vaccines, with myocarditis incidences resolving swiftly.

Official data shows eight myocarditis cases per million doses for ages 6 months to 64 years, with higher frequencies among young males.

Despite this data, Vaccine approval remains contentious, highlighting gaps between public perception and scientific findings.

Concerns about safety haven’t derailed scientific consensus on vaccine purpose.

Outcomes from rigorous safety analyses prove keen oversight and responsiveness to potential side effects.

Before recommending regular COVID-19 shots for children and healthy adults, officials emphasize the need for more evidence and trials, aligning with conservative demand for accountable health oversight.